BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 23205883)

  • 1. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.
    Sohn SY; Choi JY; Jang HW; Kim HJ; Jin SM; Kim SW; Suh S; Hur KY; Kim JH; Chung JH; Kim SW
    Thyroid; 2013 Jun; 23(6):741-7. PubMed ID: 23205883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment.
    Sohn SY; Choi JH; Kim NK; Joung JY; Cho YY; Park SM; Kim TH; Jin SM; Bae JC; Lee SY; Chung JH; Kim SW
    Thyroid; 2014 May; 24(5):872-7. PubMed ID: 24295076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low iodine diet for one week is sufficient for adequate preparation of high dose radioactive iodine ablation therapy of differentiated thyroid cancer patients in iodine-rich areas.
    Lee M; Lee YK; Jeon TJ; Chang HS; Kim BW; Lee YS; Park CS; Ryu YH
    Thyroid; 2014 Aug; 24(8):1289-96. PubMed ID: 24731156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
    Tresoldi AS; Sburlati LF; Rodari M; Schinkelshoek MS; Perrino M; De Leo S; Montefusco L; Colombo P; Arosio M; Lania AGA; Fugazzola L; Chiti A
    J Endocrinol Invest; 2014 Aug; 37(8):709-714. PubMed ID: 24844565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.
    Zevallos JP; Xu L; Yiu Y
    Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma.
    Pluijmen MJ; Eustatia-Rutten C; Goslings BM; Stokkel MP; Arias AM; Diamant M; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):428-35. PubMed ID: 12641625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
    Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
    Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iodine intake as a risk factor for BRAF mutations in papillary thyroid cancer patients from an iodine-replete area.
    Kim HJ; Park HK; Byun DW; Suh K; Yoo MH; Min YK; Kim SW; Chung JH
    Eur J Nutr; 2018 Mar; 57(2):809-815. PubMed ID: 28258306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pattern of urine iodine excretion with low iodine diet during preparation for radioactive iodine ablation in patients with thyroid cancer.
    Kang SW; Yap ZZ; Lee CR; Lee J; Jeong JJ; Nam KH; Yun MJ; Lee EJ; Chung WY; Park CS
    Head Neck; 2019 Feb; 41(2):381-387. PubMed ID: 30548084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
    Rosário PW; Calsolari MR
    Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low iodine diet in differentiated thyroid cancer: a review.
    Li JH; He ZH; Bansal V; Hennessey JV
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):3-12. PubMed ID: 26118628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
    Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ
    Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma.
    Kruijff S; Aniss AM; Chen P; Sidhu SB; Delbridge LW; Robinson B; Clifton-Bligh RJ; Roach P; Gill AJ; Learoyd D; Sywak MS
    Surgery; 2013 Dec; 154(6):1337-44; discussion 1344-5. PubMed ID: 24383104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
    Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
    Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Affecting Ablation Success After I-131 Radioactive Iodine Therapy in Low and Intermediate Risk Papillary Thyroid Cancer.
    Goksel S; Avci U
    Horm Metab Res; 2023 Oct; 55(10):677-683. PubMed ID: 37267999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
    Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
    Scheffel RS; Zanella AB; Dora JM; Maia AL
    Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.